CHE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Chemed Corp is not a good immediate buy for a beginner long-term investor with $50,000-$100,000 to deploy right now. The stock has some supportive long-term elements, including a long dividend history and recent operating strength in VITAS, but the broader setup is mixed: analyst sentiment has cooled, hedge funds are selling, technicals are stretched, and the latest pattern data points to near-term weakness. Given the user is impatient and does not want to wait for a better entry, the direct answer is to hold off rather than buy today.
CHE is trading at 441.55, essentially flat on the day, and sits just below the first resistance level at 443.80. The MACD histogram remains positive at 1.249 but is contracting, which suggests momentum is weakening. RSI_6 at 79.664 indicates the stock is overbought, even though the dataset labels it neutral. Moving averages are converging, which usually signals a less decisive trend rather than a strong breakout. Support is at 427.53, with deeper support at 411.27 and 401.22. Overall, the short-term trend is constructive but stretched, and the stock does not look like a clean entry here.
["Chemed declared its 220th consecutive quarterly dividend, reinforcing shareholder return consistency.", "Recent news highlights a quarterly dividend of $0.60 per share, showing continued capital return stability.", "RBC noted a solid Q1 print and a rare post-Q1 guidance raise, with VITAS showing strong census growth and margin outperformance.", "Oppenheimer sees long-term value creation potential, including possible value unlock from separating the businesses.", "Options positioning is bullishly skewed toward calls."]
["Hedge funds are selling, and the selling pace increased 158.47% over the last quarter.", "Several analysts have cut price targets and/or downgraded the stock recently after disappointing results and weaker outlook commentary.", "Roto-Rooter margin uncertainty remains a major concern and is masking value in the VITAS business.", "Technical momentum is fading, with MACD contraction and an overbought RSI reading.", "Pattern-based trend data suggests negative near-term performance probabilities.", "No meaningful insider buying and no recent congress trading data to support a bullish case."]
No full financial snapshot was available in the data, but analyst commentary gives a clear read on the latest quarter. The latest quarter appears to be Q1 2026, and it was strong enough for RBC to cite a rare post-Q1 guidance raise. VITAS reportedly delivered strong census growth and margin outperformance, pushing consolidated EBITDA and EPS above consensus. That is the main fundamental positive. However, the overall financial tone is still mixed because analysts also flagged weak Roto-Rooter performance and reduced guidance expectations there.
Analyst sentiment has been mixed to negative overall, though there is some recent improvement from the strongest negative revisions. RBC currently has Sector Perform with a $436 target, up from $422, while Oppenheimer is more constructive with Outperform and $500, arguing long-term value could be unlocked through separation. On the bearish side, BofA cut to Neutral with a $450 target from $595, and Jefferies Hold with $400 after disappointing Q4 and lower guidance. The Wall Street pros and cons view is split: bulls focus on VITAS strength and sum-of-the-parts value, while bears focus on Roto-Rooter margin pressure, earnings misses, and weaker guidance. Recent target revisions still lean cautious overall.
